Verona Pharma Signs $219M Agreement with Nuance Pharma to Develop and Commercialize Ensifentrine in Greater China
Shots: Verona Pharma to receive $40M including $25M upfront cash and $15M equity interest in Nuance Biotech, and is eligible to receive ~$179M in milestones along with royalties on net sales in Greater China (mainland China, Taiwan, Hong Kong and Macau) Verona Pharma granted Nuance Pharma exclusive right to develop & commercialize ensifentrine in Greater […]